We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer
Read MoreHide Full Article
Clovis Oncology, Inc. announced that the FDA has granted accelerated approval to a supplemental new drug application (sNDA) seeking label expansion of its sole marketed drug, Rubraca, beyond ovarian cancer. The sNDA was seeking label expansion for the PARP inhibitor as a monotherapy for BRCA-mutant recurrent, metastatic castrate-resistant prostate cancer (mCRPC) in patients treated with androgen receptor-directed therapy and a taxane-based chemotherapy.
Rubraca is also approved as second-line maintenance treatment for ovarian cancer and as monotherapy for BRCA-mutant ovarian cancer in third or later-line setting.
Shares of Clovis have declined 58.5% in the past year compared with the industry’s decrease of 1.3%.
The sNDA was filed based on data from a phase II TRITON2 study. Data from the phase II TRITON2 study demonstrated that mCRPC patients with BRCA mutation treated with Rubraca achieved 44% confirmed objective response rate. Moreover, 55% of the eligible patients achieved confirmed prostate-specific antigen response.
The company is conducting a confirmatory study — TRITON 3 — to support the continued approval for Rubraca for mCRPC patients. Clovis is currently enrolling patients in the phase III study, which is evaluating Rubraca in mCRPC patients with BRCA mutation and ATM mutation. The primary endpoint of the study is radiographic progression-free survival (rPFS).
The approval of Rubraca to include mCRPC patients is likely to put the drug ahead of its competitor as there no other approved PARP inhibitor for treating prostate cancer. Meanwhile, AstraZeneca and Merck’s (MRK - Free Report) regulatory application for their PARP inhibitor, Lynparza, is under review in the United States. The application seeks label expansion for Lynparza for metastatic castration-resistant prostate cancer (with HRR genetic mutations). A decision is expected in this quarter.
Meanwhile, competition for Clovis from large pharma companies in the PARP inhibitor segment is rising with availability of other PARP inhibitors including Glaxo’s (GSK - Free Report) Zejula and Pfizer’s (PFE - Free Report) Talzenna.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer
Clovis Oncology, Inc. announced that the FDA has granted accelerated approval to a supplemental new drug application (sNDA) seeking label expansion of its sole marketed drug, Rubraca, beyond ovarian cancer. The sNDA was seeking label expansion for the PARP inhibitor as a monotherapy for BRCA-mutant recurrent, metastatic castrate-resistant prostate cancer (mCRPC) in patients treated with androgen receptor-directed therapy and a taxane-based chemotherapy.
Rubraca is also approved as second-line maintenance treatment for ovarian cancer and as monotherapy for BRCA-mutant ovarian cancer in third or later-line setting.
Shares of Clovis have declined 58.5% in the past year compared with the industry’s decrease of 1.3%.
The sNDA was filed based on data from a phase II TRITON2 study. Data from the phase II TRITON2 study demonstrated that mCRPC patients with BRCA mutation treated with Rubraca achieved 44% confirmed objective response rate. Moreover, 55% of the eligible patients achieved confirmed prostate-specific antigen response.
The company is conducting a confirmatory study — TRITON 3 — to support the continued approval for Rubraca for mCRPC patients. Clovis is currently enrolling patients in the phase III study, which is evaluating Rubraca in mCRPC patients with BRCA mutation and ATM mutation. The primary endpoint of the study is radiographic progression-free survival (rPFS).
The approval of Rubraca to include mCRPC patients is likely to put the drug ahead of its competitor as there no other approved PARP inhibitor for treating prostate cancer. Meanwhile, AstraZeneca and Merck’s (MRK - Free Report) regulatory application for their PARP inhibitor, Lynparza, is under review in the United States. The application seeks label expansion for Lynparza for metastatic castration-resistant prostate cancer (with HRR genetic mutations). A decision is expected in this quarter.
Meanwhile, competition for Clovis from large pharma companies in the PARP inhibitor segment is rising with availability of other PARP inhibitors including Glaxo’s (GSK - Free Report) Zejula and Pfizer’s (PFE - Free Report) Talzenna.
Clovis Oncology, Inc. Price
Clovis Oncology, Inc. price | Clovis Oncology, Inc. Quote
Zacks Rank
Clovis currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>